Development of a new radioimmunoassay for erythropoietin using recombinant erythropoietin

Meredith Mason-Garcia, Barbara S. Beckman, Jesse W. Brookins, Jerry S Powell, Wayne Lanham, Steve Blaisdell, Len Keay, Su Chen Li, James W. Fisher

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The development of a 24 hour radioimmunoassay for erythropoietin (EPO) using EPO derived from recombinant DNA as both immunogen and ligand is described in the present paper. Mixed breed rabbits immunized with 10 μg/kg of EPO derived from a stably transfected cell line (Elanex Pharmaceuticals Inc., Bothel, Washington USA, through McDonnell Douglas Corp., St. Louis, Missouri, USA; "MD") produced antibodies to EPO with high titer (up to 1:896,000 final dilution in the tube), high affinity (8.4 × 1011 liter/M), and good specificity Purified EPO from the above source or from AmGen Biologicals (Thousand Oaks, California, USA; "AG") were successfully radioiodinated with the chloramine-T method and used as ligand in the radioimmunoassay. Standard dose-response curves prepared with EPO from both commercial sources were not significantly different and showed a sensitivity of 0.75 to 0.96 mU/tube. The dose-response curves in both systems also showed parallelism with serially diluted serum from a patient with aplastic anemia. Within-assay and between-assay precision were determined by assaying multiple replicates of a serum pool. Recovery of exogenous EPO added to a serum pool averaged 97% for both systems. The range of normal human serum EPO was determined by assaying the sera of 153 hematologically-normal adult subjects and was found to be 1.1 to 27.3 mU/ml for MD EPO and 0.5 to 16.7 mU/ml for AG EPO. Sera from several patients with hematologic abnormalities were also assayed, including those of 36 patients with anemia of end-stage renal disease (mean ± SEM, 29.5 ±4.0 mU/ml; P < 0.01). In conclusion, this new, more rapid and sensitive radioimmuno-assay system can be used to measure EPO levels in sera from normal human subjects and patients with several types of anemia, and should also be very useful in therapeutic drug monitoring of patients receiving EPO from various commercial sources.

Original languageEnglish (US)
Pages (from-to)969-975
Number of pages7
JournalKidney International
Volume38
Issue number5
StatePublished - Nov 1990
Externally publishedYes

Fingerprint

Erythropoietin
Radioimmunoassay
Serum
Anemia
Ligands
Recombinant DNA
Aplastic Anemia
Drug Monitoring
Chronic Kidney Failure
Reference Values
Rabbits
Cell Line

ASJC Scopus subject areas

  • Nephrology

Cite this

Mason-Garcia, M., Beckman, B. S., Brookins, J. W., Powell, J. S., Lanham, W., Blaisdell, S., ... Fisher, J. W. (1990). Development of a new radioimmunoassay for erythropoietin using recombinant erythropoietin. Kidney International, 38(5), 969-975.

Development of a new radioimmunoassay for erythropoietin using recombinant erythropoietin. / Mason-Garcia, Meredith; Beckman, Barbara S.; Brookins, Jesse W.; Powell, Jerry S; Lanham, Wayne; Blaisdell, Steve; Keay, Len; Li, Su Chen; Fisher, James W.

In: Kidney International, Vol. 38, No. 5, 11.1990, p. 969-975.

Research output: Contribution to journalArticle

Mason-Garcia, M, Beckman, BS, Brookins, JW, Powell, JS, Lanham, W, Blaisdell, S, Keay, L, Li, SC & Fisher, JW 1990, 'Development of a new radioimmunoassay for erythropoietin using recombinant erythropoietin', Kidney International, vol. 38, no. 5, pp. 969-975.
Mason-Garcia M, Beckman BS, Brookins JW, Powell JS, Lanham W, Blaisdell S et al. Development of a new radioimmunoassay for erythropoietin using recombinant erythropoietin. Kidney International. 1990 Nov;38(5):969-975.
Mason-Garcia, Meredith ; Beckman, Barbara S. ; Brookins, Jesse W. ; Powell, Jerry S ; Lanham, Wayne ; Blaisdell, Steve ; Keay, Len ; Li, Su Chen ; Fisher, James W. / Development of a new radioimmunoassay for erythropoietin using recombinant erythropoietin. In: Kidney International. 1990 ; Vol. 38, No. 5. pp. 969-975.
@article{a11799b83ed44aeab795cd39f762ad91,
title = "Development of a new radioimmunoassay for erythropoietin using recombinant erythropoietin",
abstract = "The development of a 24 hour radioimmunoassay for erythropoietin (EPO) using EPO derived from recombinant DNA as both immunogen and ligand is described in the present paper. Mixed breed rabbits immunized with 10 μg/kg of EPO derived from a stably transfected cell line (Elanex Pharmaceuticals Inc., Bothel, Washington USA, through McDonnell Douglas Corp., St. Louis, Missouri, USA; {"}MD{"}) produced antibodies to EPO with high titer (up to 1:896,000 final dilution in the tube), high affinity (8.4 × 1011 liter/M), and good specificity Purified EPO from the above source or from AmGen Biologicals (Thousand Oaks, California, USA; {"}AG{"}) were successfully radioiodinated with the chloramine-T method and used as ligand in the radioimmunoassay. Standard dose-response curves prepared with EPO from both commercial sources were not significantly different and showed a sensitivity of 0.75 to 0.96 mU/tube. The dose-response curves in both systems also showed parallelism with serially diluted serum from a patient with aplastic anemia. Within-assay and between-assay precision were determined by assaying multiple replicates of a serum pool. Recovery of exogenous EPO added to a serum pool averaged 97{\%} for both systems. The range of normal human serum EPO was determined by assaying the sera of 153 hematologically-normal adult subjects and was found to be 1.1 to 27.3 mU/ml for MD EPO and 0.5 to 16.7 mU/ml for AG EPO. Sera from several patients with hematologic abnormalities were also assayed, including those of 36 patients with anemia of end-stage renal disease (mean ± SEM, 29.5 ±4.0 mU/ml; P < 0.01). In conclusion, this new, more rapid and sensitive radioimmuno-assay system can be used to measure EPO levels in sera from normal human subjects and patients with several types of anemia, and should also be very useful in therapeutic drug monitoring of patients receiving EPO from various commercial sources.",
author = "Meredith Mason-Garcia and Beckman, {Barbara S.} and Brookins, {Jesse W.} and Powell, {Jerry S} and Wayne Lanham and Steve Blaisdell and Len Keay and Li, {Su Chen} and Fisher, {James W.}",
year = "1990",
month = "11",
language = "English (US)",
volume = "38",
pages = "969--975",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Development of a new radioimmunoassay for erythropoietin using recombinant erythropoietin

AU - Mason-Garcia, Meredith

AU - Beckman, Barbara S.

AU - Brookins, Jesse W.

AU - Powell, Jerry S

AU - Lanham, Wayne

AU - Blaisdell, Steve

AU - Keay, Len

AU - Li, Su Chen

AU - Fisher, James W.

PY - 1990/11

Y1 - 1990/11

N2 - The development of a 24 hour radioimmunoassay for erythropoietin (EPO) using EPO derived from recombinant DNA as both immunogen and ligand is described in the present paper. Mixed breed rabbits immunized with 10 μg/kg of EPO derived from a stably transfected cell line (Elanex Pharmaceuticals Inc., Bothel, Washington USA, through McDonnell Douglas Corp., St. Louis, Missouri, USA; "MD") produced antibodies to EPO with high titer (up to 1:896,000 final dilution in the tube), high affinity (8.4 × 1011 liter/M), and good specificity Purified EPO from the above source or from AmGen Biologicals (Thousand Oaks, California, USA; "AG") were successfully radioiodinated with the chloramine-T method and used as ligand in the radioimmunoassay. Standard dose-response curves prepared with EPO from both commercial sources were not significantly different and showed a sensitivity of 0.75 to 0.96 mU/tube. The dose-response curves in both systems also showed parallelism with serially diluted serum from a patient with aplastic anemia. Within-assay and between-assay precision were determined by assaying multiple replicates of a serum pool. Recovery of exogenous EPO added to a serum pool averaged 97% for both systems. The range of normal human serum EPO was determined by assaying the sera of 153 hematologically-normal adult subjects and was found to be 1.1 to 27.3 mU/ml for MD EPO and 0.5 to 16.7 mU/ml for AG EPO. Sera from several patients with hematologic abnormalities were also assayed, including those of 36 patients with anemia of end-stage renal disease (mean ± SEM, 29.5 ±4.0 mU/ml; P < 0.01). In conclusion, this new, more rapid and sensitive radioimmuno-assay system can be used to measure EPO levels in sera from normal human subjects and patients with several types of anemia, and should also be very useful in therapeutic drug monitoring of patients receiving EPO from various commercial sources.

AB - The development of a 24 hour radioimmunoassay for erythropoietin (EPO) using EPO derived from recombinant DNA as both immunogen and ligand is described in the present paper. Mixed breed rabbits immunized with 10 μg/kg of EPO derived from a stably transfected cell line (Elanex Pharmaceuticals Inc., Bothel, Washington USA, through McDonnell Douglas Corp., St. Louis, Missouri, USA; "MD") produced antibodies to EPO with high titer (up to 1:896,000 final dilution in the tube), high affinity (8.4 × 1011 liter/M), and good specificity Purified EPO from the above source or from AmGen Biologicals (Thousand Oaks, California, USA; "AG") were successfully radioiodinated with the chloramine-T method and used as ligand in the radioimmunoassay. Standard dose-response curves prepared with EPO from both commercial sources were not significantly different and showed a sensitivity of 0.75 to 0.96 mU/tube. The dose-response curves in both systems also showed parallelism with serially diluted serum from a patient with aplastic anemia. Within-assay and between-assay precision were determined by assaying multiple replicates of a serum pool. Recovery of exogenous EPO added to a serum pool averaged 97% for both systems. The range of normal human serum EPO was determined by assaying the sera of 153 hematologically-normal adult subjects and was found to be 1.1 to 27.3 mU/ml for MD EPO and 0.5 to 16.7 mU/ml for AG EPO. Sera from several patients with hematologic abnormalities were also assayed, including those of 36 patients with anemia of end-stage renal disease (mean ± SEM, 29.5 ±4.0 mU/ml; P < 0.01). In conclusion, this new, more rapid and sensitive radioimmuno-assay system can be used to measure EPO levels in sera from normal human subjects and patients with several types of anemia, and should also be very useful in therapeutic drug monitoring of patients receiving EPO from various commercial sources.

UR - http://www.scopus.com/inward/record.url?scp=0025052464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025052464&partnerID=8YFLogxK

M3 - Article

C2 - 2266682

AN - SCOPUS:0025052464

VL - 38

SP - 969

EP - 975

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 5

ER -